Stay updated on Open-Label Surufatinib in EU NET Patients Clinical Trial
Sign up to get notified when there's something new on the Open-Label Surufatinib in EU NET Patients Clinical Trial page.

Latest updates to the Open-Label Surufatinib in EU NET Patients Clinical Trial page
- Check2 days agoChange DetectedRevision entry updated from v3.3.3 to v3.3.4; core study details remain unchanged.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check24 days agoChange Detected- A consolidated Locations section was added listing study sites across Alabama, California, Georgia, New York, and Texas, with the previous state-specific location headings removed. The page revision was updated to v3.3.3.SummaryDifference0.6%

- Check53 days agoChange DetectedThe page revision tag was updated from v3.2.0 to v3.3.2.SummaryDifference0.0%

- Check60 days agoChange DetectedNotice about potential government funding delays was removed. The core study information remains unchanged.SummaryDifference0.3%

- Check81 days agoChange DetectedPosted study results are now visible on the page, and the study record dates have been updated to include Results First Posted 2025-07-25.SummaryDifference0.4%

- Check103 days agoChange DetectedThe page updates to include a government funding lapse notice and a status update about operating conditions, plus a new version label (v3.2.0) while removing the old version (v3.1.0).SummaryDifference3%

Stay in the know with updates to Open-Label Surufatinib in EU NET Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Open-Label Surufatinib in EU NET Patients Clinical Trial page.